Real-time Estimate
Cboe BZX
18:12:34 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
19.14
USD
|
-0.65%
|
|
+8.98%
|
+89.23%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
84.25
|
100.7
|
64.3
|
78.5
|
93.76
|
178.4
|
-
|
-
|
Enterprise Value (EV)
1 |
84.25
|
100.7
|
64.3
|
78.5
|
93.76
|
178.4
|
178.4
|
178.4
|
P/E ratio
|
17.2
x
|
-10.9
x
|
-4.72
x
|
-3.43
x
|
-13.6
x
|
-9.98
x
|
-10.4
x
|
133
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.65
x
|
4.63
x
|
2.71
x
|
2.96
x
|
5.02
x
|
7.42
x
|
5.58
x
|
3.3
x
|
EV / Revenue
|
2.65
x
|
4.63
x
|
2.71
x
|
2.96
x
|
5.02
x
|
7.42
x
|
5.58
x
|
3.3
x
|
EV / EBITDA
|
10,468,986
x
|
-15,663,863
x
|
-7,738,043
x
|
-17,668,809
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-4,549,025
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
3,883
|
3,888
|
3,892
|
5,819
|
9,219
|
9,256
|
-
|
-
|
Reference price
2 |
21.70
|
25.90
|
16.52
|
13.49
|
10.17
|
19.27
|
19.27
|
19.27
|
Announcement Date
|
25/02/20
|
25/02/21
|
17/03/22
|
16/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
31.79
|
21.76
|
23.76
|
26.5
|
18.69
|
24.04
|
31.94
|
53.97
|
EBITDA
|
8.048
|
-6.428
|
-8.31
|
-4.443
|
-
|
-
|
-
|
-
|
EBIT
1 |
4.493
|
-8.84
|
-11.22
|
-8.345
|
-15.29
|
-18.69
|
-19.46
|
2.116
|
Operating Margin
|
14.13%
|
-40.62%
|
-47.22%
|
-31.5%
|
-81.83%
|
-77.75%
|
-60.93%
|
3.92%
|
Earnings before Tax (EBT)
1 |
2.066
|
-9.196
|
-13.52
|
-19.52
|
-6.531
|
-17.87
|
-18.79
|
2.116
|
Net income
1 |
4.955
|
-9.196
|
-13.55
|
-19.6
|
-6.716
|
-17.85
|
-18.79
|
2.116
|
Net margin
|
15.59%
|
-42.26%
|
-57.03%
|
-73.97%
|
-35.94%
|
-74.23%
|
-58.84%
|
3.92%
|
EPS
2 |
1.260
|
-2.380
|
-3.500
|
-3.930
|
-0.7500
|
-1.930
|
-1.860
|
0.1450
|
Free Cash Flow
|
-
|
-
|
-
|
-17.26
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-65.13%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/02/20
|
25/02/21
|
17/03/22
|
16/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
6.372
|
5.487
|
4.407
|
4.668
|
5.803
|
11.62
|
3.799
|
4.773
|
4.776
|
5.338
|
4.668
|
5.38
|
6.234
|
7.76
|
6.64
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-2.884
|
-3.521
|
-3.284
|
-3.674
|
-3.51
|
2.123
|
-4.364
|
-4.007
|
-3.025
|
-3.894
|
-4.167
|
-4.289
|
-4.784
|
-5.531
|
-
|
Operating Margin
|
-45.26%
|
-64.17%
|
-74.52%
|
-78.71%
|
-60.49%
|
18.27%
|
-114.87%
|
-83.95%
|
-63.34%
|
-72.95%
|
-89.27%
|
-79.72%
|
-76.75%
|
-71.28%
|
-
|
Earnings before Tax (EBT)
1 |
-3.341
|
-4.156
|
-3.585
|
-4.35
|
-4.194
|
-7.392
|
-3.688
|
0.928
|
-2.148
|
-1.623
|
-3.767
|
-3.922
|
-4.451
|
-5.531
|
-
|
Net income
1 |
-3.345
|
-4.16
|
-3.585
|
-4.354
|
-4.199
|
-7.457
|
-3.693
|
0.916
|
-2.196
|
-1.743
|
-3.645
|
-3.942
|
-4.367
|
-5.584
|
-
|
Net margin
|
-52.5%
|
-75.82%
|
-81.35%
|
-93.27%
|
-72.36%
|
-64.18%
|
-97.21%
|
19.19%
|
-45.98%
|
-32.65%
|
-78.09%
|
-73.28%
|
-70.06%
|
-71.96%
|
-
|
EPS
2 |
-0.8400
|
-1.050
|
-0.8400
|
-0.9100
|
-0.9100
|
-1.180
|
-0.4400
|
0.1000
|
-0.2400
|
-0.1900
|
-0.4067
|
-0.4267
|
-0.4833
|
-0.6000
|
-0.6500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/11/21
|
17/03/22
|
17/05/22
|
09/08/22
|
15/11/22
|
16/03/23
|
30/05/23
|
15/08/23
|
21/11/23
|
21/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-17.3
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.49
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
2.06%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/02/20
|
25/02/21
|
17/03/22
|
16/03/23
|
21/03/24
|
-
|
-
|
-
|
Last Close Price
19.27
USD Average target price
28.5
USD Spread / Average Target +47.90% Consensus |
1st Jan change
|
Capi.
|
---|
| +94.49% | 178M | | -3.93% | 86.16B | | +2.76% | 40.17B | | -16.56% | 31.47B | | +54.31% | 25.24B | | -13.34% | 15.82B | | -9.12% | 11.96B | | -15.88% | 11.89B | | -42.56% | 11.61B | | +4.64% | 8.84B |
Biopharmaceuticals
|